



Immune Design  
Investor Relations Department  
Immune Design Corp. Attn:  
Accounts Payab  
601 Gateway Blvd. Suite 250  
South San Francisco, CA 94080  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: IMDZ

Last Trade:	3.68
Trade Time:	12:56 PM ET Jan 18, 2018
Change:	-0.08 <span style="color: red;">↓</span> (- 2.000%)
Day Range	3.65 - 3.80
52-Week Range	3.50 - 13.05
Volume	181,214

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Dec 10, 2017*  
[Combination of G100 with KEYTRUDA \(pembrolizumab\) Triggers Robust Systemic Responses in Follicular NHL Patients](#)
- Nov 13, 2017*  
[Immune Design to Present at Jefferies 2017 London Healthcare Conference](#)
- Nov 7, 2017*  
[Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates](#)
- Nov 1, 2017*  
[Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- Oct 27, 2017*  
[Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 7, 2017*  
[Annual Report \(10-K\)](#)
- Apr 26, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)